Compass Therapeutics Q2 EPS $(0.10), Inline, Sales $850.00K
Portfolio Pulse from Benzinga Newsdesk
Compass Therapeutics (NASDAQ:CMPX) reported Q2 earnings per share (EPS) of $(0.10), which met analyst expectations. This represents an 11.11% increase in losses compared to the same period last year. The company also reported $850,000 in sales for the quarter.
August 12, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Compass Therapeutics reported Q2 EPS of $(0.10), meeting analyst expectations but showing an 11.11% increase in losses compared to last year. Sales were $850,000 for the quarter.
The EPS met analyst expectations, which is neutral news. However, the increase in losses by 11.11% compared to last year could be a concern for investors. The sales figure of $850,000 provides some context but is not a significant driver in either direction.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100